Dorsey Wright & Associates Adaptimmune Therapeutics PLC Transaction History

Dorsey Wright & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 28, 2021	SELL	$4.0 - $9.2 $1.7 Million - $3.92 Million	-425,833 Closed	0 $0
Q3 2020 Oct 28, 2020	BUY	$7.66 - $10.78 $3.26 Million - $4.59 Million	425,833 New	425,833 $3.4 Million
Q4 2018 Jan 07, 2019	SELL	$3.76 - $14.16 $1.43 Million - $5.4 Million	-381,348 Closed	0 $0
Q3 2018 Oct 12, 2018	SELL	$8.27 - $13.56 $1.68 Million - $2.76 Million	-203,265 Reduced 34.77%	381,348 $5.17 Million
Q2 2018 Jul 06, 2018	BUY	$10.42 - $13.74 $6.09 Million - $8.03 Million	584,613 New	584,613 $6.98 Million

160M

42.8K

42.1K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $199M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Dorsey Wright & Associates, based on Form 13F filings with the SEC.

Stay updated on Dorsey Wright & Associates with notifications on news.